Healing with cutting-edge research at the Department of Hematology, Oncology and Rheumatology
At Heidelberg University Hospital, with over 300 stem-cell transplants per year, you will find one of the largest and most prestigious centers for hematology, oncology, and rheumatology in Europe. A highly specialized team of physicians and scientists has been gathered under the direction of Professor Dr. Carsten Müller-Tidow, which sees as many patients per year as few other centers and thus, has extensive experience especially in the treatment of multiple myeloma, leukemia, and lymphoma. This is evident by the treatment results: The chances of recovery after stem-cell transplantation are above average good for our patients.
"A concern of mine is that all patients receive personal treatment. We are steadily implementing this goal despite the large number of patients, and give each of our patients an individual contact person who accompanies him/her through the daily activities of the hospital."
Professor Dr. Carsten Müller-Tidow,
Medical Director of the Department of Hematology, Oncology, and Rheumatology
- Multiple myeloma
- Acute leukemia
- Chronic myelogenous leukemia (CML)
- Lymphocytic leukemia
- Lymphoma (e.g., Hodgkin's lymphoma and non-Hodgkin's lymphoma)
- Hairy cell leukemia
We also specialize in other hematological diseases such as:
- Hemolytic anemia
- Sarcoma (malignant bone tumors)
CAR T-cell Therapy
Since Spring 2018, it is finally time: We can offer the therapy of the future in acute leukemia and for the treatment of lymphoma, now. In this cell therapy, immune system cells (T-cells - patients' or from a donor) are genetically re-programmed so that they destroy the tumor cells. The chances of recovery are very good. We would be happy to inform you whether this type of therapy might also have promising results for your case.
At a glance:
this distinguishes us
- Personal care of our 2700 patients per year
- Close integration of research and patient care allows therapies of the future
- Above average good chances of recovery
- Avoiding inpatient stays even for patients with malignant diseases! Close integration of our outpatient clinics and day hospital.
- 30 specialists in Hematology and Oncology Cooperation with other physician teams of the University Hospital
- Our own bone marrow and stem-cell transplantation station
Therapies of the future available today
The close integration of implementation and research enables us to offer innovative, promising therapies. Thus, in the frame of clinical studies, we use the latest medications that are not yet approved for use in other places - but are already delivering very promising results for efficacy. In this way, at Heidelberg we can also treat patients whose therapy was unsuccessful elsewhere.
Innovative therapies with the most promising chances of recovery
Cell therapies with bone marrow and blood stem-cell transplantation have been our core expertise for many years. In treatment, our focus is primarily on:
- Autologous stem-cell transplantation
This form of therapy is particularly suitable for patients with patients with multiple myeloma. Treatment is sometimes even possible as an outpatient (treatment period approx. 4 weeks)
- Allogeneic stem-cell transplantation (treatment period approx. 3 months)
- Chemotherapy and Immunotherapy
- Classical radiation
- Tumor vaccination
Pioneering research: Target-oriented treatment through
Since 1985, when one of the world's first stem-cell transplantations was performed here, Heidelberg has played a pioneering role in stem-cell research. Thus, among other things, our physicians are working on leukemia and lymphoma research for the benefit of patients worldwide. For example, peripheral blood stem-cell therapy has been driven forward significantly by outstanding research of Heidelberg physicians and scientists. Among other things, the research and production of novel cell therapies and vaccines is a specialization of our department. Close cooperation of our hospital with the German Cancer Research Center and the National Center for Tumor Diseases underscores the strength of Heidelberg research.
Special immune system protection: Our own bone marrow and stem-cell transplantation station
One of our special features is our own bone marrow and stem-cell transplantation station with 18 rooms. These are specially equipped with "HEPA filters": the air is specially filtered to minimize the risk of infection for our immunocompromised patients.
For the same reason, there are no long transport distances or transfers of our patients between different stations: the intensive care unit is integrated into the stem-cell transplantation unit. Almost all patients thus receive the best possible therapy, monitoring, and care, directly at our special station for bone marrow and stem-cell transplantation.
At the highest level: Comprehensive care by our specialists on site.
In the Department of Hematology, a large specialist team of more than 30 physicians awaits you. These individual experts come together at the "Tumor Board," where they discuss your particular case and present a personalized treatment plan concept. In this way, we find the best possible therapy - and above all, therapy promising the most likely success - for each patient.
Our experience is appreciated: Patients from all over the world give us their trust.
Each year we record 760 new patients; 270 come with the diagnosis of leukemia, 280 with multiple myeloma, and 210 with lymphoma. We perform more than 200 autologous and 100 allogeneic stem-cell transplantations per year.